PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06244992)
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 when administered as a monotherapy. Phase 2a (Part B) will assess the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy in patients suitable for anti- PD-1/L1 monotherapy. The study aims to understand how PTT-936, alone or in combination, impacts tumor progression and patients' overall response.
Who can join: Review the eligibility criteria below.
Location: Precision NextGen Oncology and Research Center — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Precision NextGen Oncology and Research Center — Beverly Hills, California
- D&H Cancer Research Center — Margate, Florida
- The START Center — San Antonio, Texas
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
- Beijing Cancer Hospital — Beijing,
- Cancer Hospital, Chinese Academy of Medical Sciences — Beijing,
📞 Contact the Study Coordinator
Phone: (424) 777-0708
Email: RebeccaG@NextGenOnc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — San Francisco, California
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Los Angeles, California
- A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors — San Diego, California
- Study of XB010 in Subjects With Solid Tumors — Irvine, California
Explore by condition: All Locally Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.